Want to see HK:2269 full AI Analyst Report?
Top Page
Wuxi Biologics (Cayman)
(2269)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$40.00
▲(11.98% Upside)
Action:Reiterated
Date:05/03/26
The score is driven primarily by solid fundamentals—healthy profitability and a low-leverage balance sheet—tempered by slowing revenue growth and weaker cash conversion. Technical signals are a meaningful drag due to a bearish trend (below major moving averages with negative MACD), while valuation is moderately supportive with a low P/E.
Positive Factors
High Profitability Margins
Sustained high gross, EBIT and net margins provide structural earnings power that funds reinvestment, supports returns through business cycles, and creates a buffer against pricing pressure. Healthy margins improve ability to finance growth without meaningfully adding leverage.
Negative Factors
Slowing Revenue Growth
A marked deceleration in top-line growth reduces forward visibility for capacity utilization and long-term margin expansion. Slow growth can indicate market saturation, increased competition or client program timing risks that constrain sustainable scale benefits.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability Margins
Sustained high gross, EBIT and net margins provide structural earnings power that funds reinvestment, supports returns through business cycles, and creates a buffer against pricing pressure. Healthy margins improve ability to finance growth without meaningfully adding leverage.
Read all positive factors
Wuxi Biologics (Cayman) (2269) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$153.23B
Dividend YieldN/A
Average Volume (3M)32.67M
Price to Earnings (P/E)26.9
Beta (1Y)1.71
Revenue Growth16.79%
EPS Growth47.14%
CountryHK
Employees13,252
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.19
Shares Outstanding4,143,562,500
10 Day Avg. Volume33,789,006
30 Day Avg. Volume32,668,415
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)2.53
Price to Sales (P/S)5.48
P/FCF Ratio42.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$50.49Price Target Upside41.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)1.28
Revenue Forecast (FY)HK$25.24B
Wuxi Biologics (Cayman) Business Overview & Revenue Model
Company Description
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufactu...
How the Company Makes Money
Wuxi Biologics makes money primarily by providing fee-based outsourced services to biopharmaceutical customers across the biologics lifecycle. Its key revenue streams typically include: (1) discovery and preclinical services—project-based fees for...
Wuxi Biologics (Cayman) Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
67
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 21.79B | 18.68B | 17.03B | 15.27B | 10.29B |
| Gross Profit | 10.02B | 7.65B | 6.83B | 6.72B | 4.83B |
| EBITDA | 7.92B | 6.43B | 5.50B | 6.22B | 4.51B |
| Net Income | 4.91B | 3.36B | 3.40B | 4.42B | 3.39B |
Balance Sheet | |||||
| Total Assets | 63.72B | 56.98B | 56.58B | 49.56B | 44.03B |
| Cash, Cash Equivalents and Short-Term Investments | 15.74B | 10.71B | 11.24B | 8.71B | 11.13B |
| Total Debt | 3.11B | 4.94B | 4.56B | 4.42B | 4.30B |
| Total Liabilities | 10.66B | 11.50B | 12.56B | 13.35B | 11.33B |
| Stockholders Equity | 47.27B | 41.82B | 40.33B | 35.05B | 32.28B |
Cash Flow | |||||
| Free Cash Flow | 2.80B | 1.29B | 437.20M | -326.72M | -3.09B |
| Operating Cash Flow | 6.39B | 5.22B | 4.67B | 5.54B | 3.43B |
| Investing Cash Flow | -3.38B | -3.94B | -3.23B | -5.91B | -9.60B |
| Financing Cash Flow | -1.95B | -2.75B | 1.96B | -2.59B | 8.21B |
Wuxi Biologics (Cayman) Technical Analysis
Positive
35.72
Price Trends
33.70
Positive
34.64
Positive
35.25
Positive
Market Momentum
1.55
Negative
55.80
Neutral
59.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2269, the sentiment is Positive. The current price of 35.72 is above the 20-day moving average (MA) of 35.56, above the 50-day MA of 33.70, and above the 200-day MA of 35.25, indicating a bullish trend. The MACD of 1.55 indicates Negative momentum. The RSI at 55.80 is Neutral, neither overbought nor oversold. The STOCH value of 59.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2269.
Wuxi Biologics (Cayman) Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$20.61B | 101.26 | 11.29% | ― | 40.78% | 410.73% | |
64 Neutral | HK$153.23B | 26.90 | 10.64% | ― | 16.79% | 47.14% | |
61 Neutral | HK$67.75B | 36.96 | 11.22% | 1.04% | 16.83% | -8.65% | |
58 Neutral | HK$2.21B | 41.75 | 1.98% | ― | 0.61% | 766.67% | |
58 Neutral | HK$2.52B | 10.60 | 5.57% | ― | -12.90% | 33.65% | |
54 Neutral | HK$28.78B | -6.70 | -12.72% | ― | 60.96% | -117.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2269
Wuxi Biologics (Cayman)
36.98
8.98
32.07%
HK:1548
Genscript Biotech
13.22
-3.20
-19.49%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
23.20
5.01
27.51%
HK:1521
Frontage Holdings Corp.
1.08
-0.27
-20.00%
HK:1873
Viva Biotech Holdings
1.21
-0.31
-20.39%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
50.45
29.65
142.55%
Wuxi Biologics (Cayman) Corporate Events
WuXi Biologics Wins Full Shareholder Backing at 2026 AGM
Jun 10, 2026
WuXi Biologics said shareholders approved all resolutions at its 10 June 2026 annual general meeting, including the 2025 audited financial statements and the re-election of three directors, with most items passing with overwhelming majorities. Inv...
Wuxi Biologics Grants Time-Based Restricted Shares to 21 Employees
Jun 9, 2026
Wuxi Biologics has approved the grant of 288,441 restricted shares at no purchase cost to 21 employees under its Restricted Share Award Scheme, with a market reference price of HK$29.94 per share on the grant date. The award vests in four equal an...
WuXi Biologics Schedules 2026 Business Update Calls for Investors
May 31, 2026
WuXi Biologics has announced that it will host two business update conference calls on June 1, 2026, one in Chinese and one in English, to brief shareholders and potential investors on its latest operational developments. The company has also publ...
WuXi Biologics Launches US$400 Million Share Buyback Plan
May 26, 2026
WuXi Biologics has resolved to activate its shareholder-approved mandate to repurchase shares on the Hong Kong Stock Exchange, authorizing on-market buybacks of up to US$400 million under its existing and future general repurchase mandates. The bo...
WuXi Biologics Sets 2026 AGM to Vote on Board, Auditors and New Share Mandate
May 19, 2026
WuXi Biologics (Cayman) Inc. has called its annual general meeting for June 10, 2026, to be held in Shanghai, where shareholders will review the company’s audited financial statements for the year ended December 31, 2025 and receive reports ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.